中国临床药理学杂志2017，Vol.33Issue(9)：778-781,4.DOI:10.13699/j.cnki.1001-6821.2017.09.003
曲妥珠单抗治疗晚期乳腺癌患者的心脏毒性研究
Clinical trial of the cardiotoxicity of trastuzumab in the treatment of patients with metastatic breast cancer
摘要
Abstract
Objective To study the cardiotoxicity of trastuzumab in human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer patients.Methods We retrospectively collected the clinical data of general characteristic,left ventricular ejection fraction (LVEF) and clinical efficacy in 102 HER2 positive metastatic breast cancer patients treated with trastuzumab and analyzed the factors which influence the changes of LVEF and the incidence of cardiotoxicity induced by trastuzumab.Results In all of the 102 patients,the complete remission and partial remission were 7 cases (6.86％) and 73 cases (71.57％) in patients firstly treated with trastuzumab-based regimens respectively.The LVEF value was (72.85 ± 4.64) ％ at baseline and decreased to (66.05 ±5.96)％ and (65.15 ±3.38)％ as the valley points at21 and 39 months in patients who continually used trastuzumab.The progression free (PFS) of the first use of trastuzumab containing regimen and trastuzumab usage time were the clinical factors influencing the LVEF decreased value (P ＜ 0.05).The cumulative incidence of trastuzumab associated cardiotoxicity (TACT) was 14.71％ (15 cases) in the whole course of LVEF monitoring.All patients had no occurrence of heart failure and trastuzumab treatment related death caused by trastuzumab.Conclusion The heart function deceased and recovered periodically under treatment with trastuzumab in metastatic breast cancer.The incidence of cardiotoxicity was stable.Long term use of trastuzumab was well tolerated and safe.关键词
曲妥珠单抗/乳腺肿瘤/心脏功能/左心室射血分数/心脏毒性Key words
trastuaumab/breast neoplasms/cardiac function/left ventricular ejection fraction/cardiotoxicity分类
医药卫生引用本文复制引用
黄平,刘雅娟,陈占红,郑亚兵,孙燕,黄健,曹文明,邵喜英,王晓稼..曲妥珠单抗治疗晚期乳腺癌患者的心脏毒性研究[J].中国临床药理学杂志,2017,33(9):778-781,4.基金项目
浙江省医药卫生科技计划基金资助项目(2015RCB005,2016KYA046) （2015RCB005,2016KYA046）
